Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis
by Zacks Equity Research
Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
by Zacks Equity Research
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.52% and 0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Why Earnings Season Could Be Great for Zimmer Biomet (ZBH)
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet Grows Internationally Despite Pricing Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses strength in the EMEA and APAC regions as well as in the Spine & CMF business.
Why Is Zimmer (ZBH) Down 8.2% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings
by Zacks Equity Research
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Zimmer Biomet Solid on Global Prospects Despite Price Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.
Zimmer Biomet (ZBH) Jumps: Stock Rises 6.4%
by Zacks Equity Research
Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
Zimmer Biomet (ZBH) Meets Q4 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.00% and 0.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions
by Zacks Equity Research
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
Medical Products Industry Outlook: Plenty of Upside Left
by Zacks Equity Research
The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.